Lifecore Biomedical Inc. (LFCR) - Net Assets
Based on the latest financial reports, Lifecore Biomedical Inc. (LFCR) has net assets worth $16.09 Million USD as of May 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($229.50 Million) and total liabilities ($213.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lifecore Biomedical Inc. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.09 Million |
| % of Total Assets | 7.01% |
| Annual Growth Rate | N/A |
| 5-Year Change | -113.16% |
| 10-Year Change | -106.22% |
| Growth Volatility | 210.74 |
Lifecore Biomedical Inc. - Net Assets Trend (1996–2026)
This chart illustrates how Lifecore Biomedical Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Lifecore Biomedical Inc..
Annual Net Assets for Lifecore Biomedical Inc. (1996–2026)
The table below shows the annual net assets of Lifecore Biomedical Inc. from 1996 to 2026. Also explore how fast is Lifecore Biomedical Inc. growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-05-31 | $-14.20 Million | -1163.02% |
| 2025-05-31 | $1.34 Million | -88.19% |
| 2024-05-31 | $11.31 Million | -87.12% |
| 2023-05-31 | $87.82 Million | -18.64% |
| 2022-05-31 | $107.94 Million | -46.77% |
| 2021-05-31 | $202.78 Million | -12.23% |
| 2020-05-31 | $231.04 Million | -14.47% |
| 2019-05-31 | $270.14 Million | +6.96% |
| 2018-05-31 | $252.56 Million | +10.70% |
| 2017-05-31 | $228.15 Million | +7.44% |
| 2016-05-31 | $212.35 Million | -3.53% |
| 2015-05-31 | $220.11 Million | +7.50% |
| 2014-05-31 | $204.76 Million | +13.50% |
| 2013-05-31 | $180.41 Million | +19.04% |
| 2012-05-31 | $151.56 Million | +10.04% |
| 2011-05-31 | $137.73 Million | +3.96% |
| 2010-05-31 | $132.47 Million | +4.15% |
| 2009-05-31 | $127.20 Million | +9.64% |
| 2008-05-31 | $116.02 Million | +3.52% |
| 2007-05-31 | $112.07 Million | +29.09% |
| 2006-05-31 | $86.82 Million | +18.08% |
| 2005-05-31 | $73.53 Million | +16.52% |
| 2004-05-31 | $63.10 Million | +5.87% |
| 2003-05-31 | $59.60 Million | +3.58% |
| 2002-05-31 | $57.54 Million | +13.11% |
| 2001-05-31 | $50.87 Million | -10.74% |
| 2000-05-31 | $57.00 Million | +79.24% |
| 1999-05-31 | $31.80 Million | -5.64% |
| 1998-05-31 | $33.70 Million | -5.34% |
| 1997-05-31 | $35.60 Million | -2.73% |
| 1996-05-31 | $36.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lifecore Biomedical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19190100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | % |
| Other Components | $208.96 Million | % |
| Total Equity | $-14.20 Million | 100.00% |
Lifecore Biomedical Inc. Competitors by Market Cap
The table below lists competitors of Lifecore Biomedical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daeho Al Co. Ltd.
KO:069460
|
$156.77 Million |
|
Sparebanken Ost
OL:SPOG
|
$156.83 Million |
|
1911 Gold Corp
V:AUMB
|
$156.92 Million |
|
Scottie Resources Corp
V:SCOT
|
$156.97 Million |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
$156.64 Million |
|
Valens
NYSE:VLN
|
$156.62 Million |
|
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
|
$156.62 Million |
|
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
|
$156.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lifecore Biomedical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 1,336,000 to -14,202,000, a change of -15,538,000 (-1163.0%).
- Net loss of 6,156,000 reduced equity.
- Share repurchases of 1,942,286 reduced equity.
- Other factors decreased equity by 7,439,714.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.16 Million | -43.35% |
| Share Repurchases | $1.94 Million | -13.68% |
| Other Changes | $-7.44 Million | -52.38% |
| Total Change | $- | -1163.02% |
Book Value vs Market Value Analysis
This analysis compares Lifecore Biomedical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-05-31 | $4.68 | $4.14 | x |
| 1997-05-31 | $3.19 | $4.14 | x |
| 1998-05-31 | $2.53 | $4.14 | x |
| 1999-05-31 | $3.18 | $4.14 | x |
| 2000-05-31 | $3.54 | $4.14 | x |
| 2001-05-31 | $3.04 | $4.14 | x |
| 2002-05-31 | $3.08 | $4.14 | x |
| 2003-05-31 | $2.49 | $4.14 | x |
| 2004-05-31 | $2.61 | $4.14 | x |
| 2005-05-31 | $2.93 | $4.14 | x |
| 2006-05-31 | $3.31 | $4.14 | x |
| 2007-05-31 | $4.15 | $4.14 | x |
| 2008-05-31 | $4.25 | $4.14 | x |
| 2009-05-31 | $4.75 | $4.14 | x |
| 2010-05-31 | $4.91 | $4.14 | x |
| 2011-05-31 | $5.11 | $4.14 | x |
| 2012-05-31 | $5.73 | $4.14 | x |
| 2013-05-31 | $6.71 | $4.14 | x |
| 2014-05-31 | $7.49 | $4.14 | x |
| 2015-05-31 | $7.99 | $4.14 | x |
| 2016-05-31 | $7.76 | $4.14 | x |
| 2017-05-31 | $8.20 | $4.14 | x |
| 2018-05-31 | $9.05 | $4.14 | x |
| 2019-05-31 | $9.44 | $4.14 | x |
| 2020-05-31 | $7.92 | $4.14 | x |
| 2021-05-31 | $6.92 | $4.14 | x |
| 2022-05-31 | $3.66 | $4.14 | x |
| 2023-05-31 | $2.98 | $4.14 | x |
| 2024-05-31 | $0.31 | $4.14 | x |
| 2025-05-31 | $0.04 | $4.14 | x |
| 2026-05-31 | $-0.38 | $4.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lifecore Biomedical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.02%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-100.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -11.48% | -168.00% | 0.07x | 1.05x | $-7.86 Million |
| 1997 | -24.16% | -90.53% | 0.19x | 1.41x | $-12.16 Million |
| 1998 | -8.61% | -8.66% | 0.79x | 1.26x | $-6.27 Million |
| 1999 | -8.81% | -7.91% | 0.87x | 1.28x | $-5.98 Million |
| 2000 | -7.16% | -1.91% | 1.69x | 2.22x | $-9.58 Million |
| 2001 | -37.70% | -9.84% | 1.59x | 2.41x | $-23.77 Million |
| 2002 | -2.66% | -0.81% | 1.70x | 1.93x | $-7.08 Million |
| 2004 | 4.71% | 1.51% | 2.07x | 1.51x | $-3.25 Million |
| 2005 | 7.50% | 2.63% | 2.05x | 1.39x | $-1.80 Million |
| 2006 | 10.17% | 3.73% | 1.95x | 1.40x | $146.10K |
| 2007 | 26.48% | 13.87% | 1.49x | 1.28x | $18.17 Million |
| 2008 | 11.83% | 5.68% | 1.58x | 1.32x | $2.10 Million |
| 2009 | 6.08% | 3.28% | 1.54x | 1.20x | $-4.99 Million |
| 2010 | 3.05% | 1.67% | 1.19x | 1.53x | $-9.09 Million |
| 2011 | 2.88% | 1.42% | 1.34x | 1.52x | $-9.69 Million |
| 2012 | 8.48% | 4.00% | 1.14x | 1.85x | $-2.28 Million |
| 2013 | 12.64% | 5.11% | 1.52x | 1.63x | $4.72 Million |
| 2014 | 9.43% | 4.02% | 1.52x | 1.54x | $-1.16 Million |
| 2015 | 6.20% | 2.51% | 1.56x | 1.59x | $-8.30 Million |
| 2016 | -5.52% | -2.15% | 1.58x | 1.63x | $-32.71 Million |
| 2017 | 4.67% | 1.99% | 1.49x | 1.58x | $-12.07 Million |
| 2018 | 9.83% | 4.74% | 1.30x | 1.60x | $-427.20K |
| 2019 | 0.79% | 0.38% | 1.07x | 1.92x | $-24.89 Million |
| 2020 | -16.53% | -23.86% | 0.30x | 2.34x | $-61.30 Million |
| 2021 | -15.93% | -32.01% | 0.20x | 2.48x | $-52.57 Million |
| 2022 | -90.26% | -52.44% | 0.63x | 2.73x | $-108.23 Million |
| 2023 | -132.90% | -104.89% | 0.41x | 3.13x | $-125.50 Million |
| 2024 | 106.17% | 9.37% | 0.51x | 22.44x | $10.88 Million |
| 2025 | -2897.98% | -30.04% | 0.54x | 179.15x | $-38.85 Million |
| 2026 | 0.00% | -18.02% | 0.15x | 0.00x | $-4.74 Million |
Industry Comparison
This section compares Lifecore Biomedical Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $290,420,616
- Average return on equity (ROE) among peers: -51.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lifecore Biomedical Inc. (LFCR) | $16.09 Million | -11.48% | 13.26x | $156.71 Million |
| Aurora Cannabis Inc (ACB) | $1.08 Million | -29.24% | 0.07x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $140.89 Million | 0.00% | 0.10x | $138.64 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $241.89 Million |
| Alkermes Plc (ALKS) | $1.11 Billion | -4.33% | 0.82x | $7.72 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $3.58 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $5.80 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.00 Million | -54.00% | 0.38x | $279.44 Million |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more